Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Xenon Pharmaceuticals Inc

Healthcare US XENE

52.99USD
-0.47(0.88%)

Last update at 2026-06-04T20:00:00Z

Day Range

52.9554.63
LowHigh

52 Week Range

27.9850.99
LowHigh

Fundamentals

  • Previous Close 53.46
  • Market Cap2895.74M
  • Volume1363521
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-219.97174M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -96.33300M
  • Diluted EPS TTM-2.72

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -125.25500M -78.88800M -29.09400M -41.61800M -34.49700M
Minority interest - - - - -
Net income -125.37300M -78.88200M -28.83700M -41.59500M -34.49700M
Selling general administrative 32.81M 21.97M 12.94M 10.80M 8.38M
Selling and marketing expenses - - - - -
Gross profit 9.43M 18.44M 32.17M 6.83M -6.00000M
Reconciled depreciation 1.62M 0.91M 0.64M 0.43M 0.59M
Ebit -130.76700M -79.89900M -31.94500M -42.81900M -36.80000M
Ebitda -129.14300M -78.99300M -31.30100M -40.03700M -36.21400M
Depreciation and amortization 1.62M 0.91M 0.64M 2.78M 0.59M
Non operating income net other 3.89M 0.10M 2.69M 2.63M 0.52M
Operating income -129.14300M -78.99300M -31.30100M -42.81900M -38.01600M
Other operating expenses 138.58M 97.43M 63.47M 49.65M 38.02M
Interest expense -5.51200M 1.01M 0.48M 1.43M 1.39M
Tax provision 0.12M -0.00600M -0.25700M -0.02300M -0.02400M
Interest income 8.71M 0.47M 2.28M 2.35M 1.22M
Net interest income 8.71M 0.47M 1.80M 0.92M -0.17800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.12M -0.00600M -0.25700M -0.02300M 4.91M
Total revenue 9.43M 18.44M 32.17M 6.83M 0.00000M
Total operating expenses 138.58M 97.43M 63.47M 49.65M 32.02M
Cost of revenue - - - 0.00000M 6.00M
Total other income expense net 3.89M 0.10M 2.21M 1.20M 3.70M
Discontinued operations - - - - -
Net income from continuing ops -125.37300M -78.88200M -28.83700M -41.59500M -38.89500M
Net income applicable to common shares -124.93600M -77.08700M -28.01300M -40.02700M -31.61600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 964.80M 754.15M 572.01M 189.19M 147.70M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.01M 8.21M 7.25M 4.79M 2.69M
Total liab 36.88M 32.65M 21.97M 17.83M 55.72M
Total stockholder equity 927.92M 721.50M 550.03M 171.35M 91.98M
Deferred long term liab - - - - -
Other current liab 17.38M 13.72M 0.60M 7.83M 6.34M
Common stock 1436.37M 1065.14M 783.17M 397.75M 294.24M
Capital stock 1436.37M 1065.14M 790.90M 405.48M 301.98M
Retained earnings -665.14000M -482.74700M -357.37400M -278.49200M -249.65500M
Other liab - - - - 0.71M
Good will - - - - -
Other assets 306.19M 143.66M 0.47M 0.52M 0.24M
Cash 148.64M 57.24M 175.69M 45.01M 24.75M
Cash and equivalents - - - - -
Total current liabilities 27.27M 22.70M 14.32M 14.78M 43.38M
Current deferred revenue - - 9.29M 3.64M 29.74M
Net debt -137.74000M -46.80700M -167.43100M -41.69400M -8.30500M
Short term debt 1.30M 0.49M 0.60M 0.27M 4.82M
Short long term debt - - - - 4.65M
Short long term debt total 10.90M 10.44M 8.26M 3.31M 16.45M
Other stockholder equity 156.76M 142.11M 117.50M 45.36M 40.65M
Property plant equipment - 6.50M 4.47M 3.55M 1.66M
Total current assets 644.96M 600.30M 559.02M 181.78M 144.87M
Long term investments 292.79M 128.68M - - -
Net tangible assets - 721.50M 542.30M 163.62M 84.25M
Short term investments 489.44M 534.85M 376.09M 131.99M 116.60M
Net receivables 0.87M 0.99M 2.77M 1.82M 0.81M
Long term debt - - - - 10.89M
Inventory 0.00000M -0.98600M -2.76500M -1.82200M -
Accounts payable 8.60M 8.49M 3.82M 3.04M 2.47M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.07700M -3.00000M -0.99000M -0.99000M -0.99000M
Additional paid in capital - - - - -
Common stock total equity - 1065.14M 783.17M 397.75M 294.24M
Preferred stock total equity - - 7.73M 7.73M 7.73M
Retained earnings total equity - -482.74700M -357.37400M -278.49200M -249.65500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 7.40M 7.75M 8.06M 7.40M 2.59M
Deferred long term asset charges - - - - 0.24M
Non current assets total 319.84M 153.85M 12.99M 7.40M 2.83M
Capital lease obligations 10.90M 10.44M 8.26M 3.31M 0.91M
Long term debt total - - - - 10.89M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -293.10900M -244.72000M -14.18700M -65.05100M -28.48000M
Change to liabilities 8.06M 2.97M 2.02M 4.54M 0.78M
Total cashflows from investing activities -296.00300M -246.77000M -16.82400M -66.29100M -28.98700M
Net borrowings - - -16.74300M -16.74300M 8.45M
Total cash from financing activities 278.47M 447.54M 85.80M 27.52M 111.59M
Change to operating activities -10.49500M -1.51700M -0.26900M -0.82000M -0.92800M
Net income -125.37300M -78.88200M -28.83700M -41.59500M -34.49700M
Change in cash -118.44600M 130.68M 20.25M -42.99900M 47.27M
Begin period cash flow 175.69M 45.01M 24.75M 67.75M 20.49M
End period cash flow 57.24M 175.69M 45.01M 24.75M 67.75M
Total cash from operating activities -98.43000M -69.50200M -48.12400M -4.63200M -34.72400M
Issuance of capital stock 277.77M 447.28M 102.46M 27.40M 102.85M
Depreciation 1.62M 0.91M 0.64M 0.43M 0.59M
Other cashflows from investing activities - - - -65.05100M -28.48000M
Dividends paid - - - - -
Change to inventory - -2.97100M -2.02200M -4.54100M -0.78300M
Change to account receivables 1.76M -0.45900M -1.03200M -0.65300M 0.17M
Sale purchase of stock 0.70M 0.26M 102.54M 27.52M 103.14M
Other cashflows from financing activities 0.70M 0.26M 0.08M 0.12M 8.74M
Change to netincome 23.06M 11.12M 5.94M 2.49M -1.12700M
Capital expenditures 2.89M 2.05M 2.64M 1.24M 0.51M
Change receivables 1.76M -0.45900M -1.03200M -0.65300M 0.17M
Cash flows other operating -7.56100M -5.15900M -27.07900M 29.63M -0.92800M
Exchange rate changes - - - - -0.61200M
Cash and cash equivalents changes -115.96200M 131.27M 20.85M -43.40500M 47.27M
Change in working capital -0.67600M -2.64700M -26.08900M 33.52M 0.03M
Stock based compensation 20.38M 10.02M 5.68M 2.92M 2.62M
Other non cash items 5.66M 1.05M 0.77M 0.22M -4.11400M
Free cash flow -101.32400M -71.55200M -50.76100M -5.87200M -35.23100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
XENE
Xenon Pharmaceuticals Inc		 -0.47 0.88% 52.99 - - 181.44 3.35 10874.63 -11.8089
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8

Key Executives

Name Title Year Born
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA Pres, CEO & Director 1976
Ms. Sherry Aulin Chief Financial Officer 1984
Dr. Christopher John Kenney M.D. Chief Medical Officer 1971
Ms. Jodi Regts M.B.A., B.A., MBA VP of Corp. Affairs & Investor Relations NA
Ms. Andrea DiFabio J.D. Chief Legal Officer & Corp. Sec. 1968
Ms. Shelley McCloskey B.A. Exec. VP of HR 1960
Dr. Robin P. Sherrington Ph.D. Exec. VP of Strategy & Innovation 1961
Dr. James R. Empfield Ph.D. Exec. VP of Drug Discovery 1961
Ms. Sheila M. Grant M.B.A., M.Sc., MBA Exec. VP of R&D Operations NA
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. Chief Commercial Officer 1979

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions